Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1
Stem Cell Research & Therapy2014Vol. 5(2), pp. 40–40
Citations Over TimeTop 10% of 2014 papers
Xiangyu Zou, Guangyuan Zhang, Zhongliang Cheng, Yin Deming, Tao Du, Guanqun Ju, Shuai Miao, Guohua Liu, Mujun Lu, Yingjian Zhu
Abstract
A single administration of MVs immediately after ischemic AKI could ameliorate renal injury in both the acute and chronic stage, and the anti-inflammatory property of MVs through suppression of CX3CL1 may be a potential mechanism. This establishes a substantial foundation for future research and treatment.
Related Papers
- → Umbilical Cord Lining Membrane and Wharton's Jelly-Derived Mesenchymal Stem Cells: the Similarities and Differences(2011)40 cited
- → Absence of Wharton’s jelly: case report(2014)7 cited
- → Announcing Exosomes and Microvesicles, the Official Journal of the American Society for Exosomes and Microvesicles(2013)1 cited
- Absence of Wharton's jelly: case report Ausência da geleia de Wharton: relato de caso(2014)
- → Investigating the expression of mesenchymal markers in stem cells of human umbilical cord matrix (Wharton's jelly)(2022)